Incannex Healthcare Limited (IXHL)
Automate Your Wheel Strategy on IXHL
With Tiblio's Option Bot, you can configure your own wheel strategy including IXHL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IXHL
- Rev/Share 0.0014
- Book/Share 0.0548
- PB 3.766
- Debt/Equity 4.2456
- CurrentRatio 1.7986
- ROIC -2.1111
- MktCap 19319985.0
- FreeCF/Share -0.4474
- PFCF -2.4499
- PE -0.2941
- Debt/Assets 0.3689
- DivYield 0
- ROE -2.0284
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced the recent appointment of four distinguished experts to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board:
Read More
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules
Published: March 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Funds to support the advancement of Incannex's IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase 3 study. Funds to support the advancement of Incannex's IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase 3 study.
Read More
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025
Published: February 18, 2025 by: Newsfile Corp
Sentiment: Neutral
Dallas, Texas--(Newsfile Corp. - February 18, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the second quarter of fiscal year 2025, Incannex Healthcare Inc. reported R&D costs of $1.4M, a decrease from $2.6M in the same period of the previous year.
Read More
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended December 31, 2024.
Read More
About Incannex Healthcare Limited (IXHL)
- IPO Date 2022-03-02
- Website https://www.incannex.com.au
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Joel Bradley Latham
- Employees 9